99 related articles for article (PubMed ID: 12209961)
1. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
[TBL] [Abstract][Full Text] [Related]
2. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.
Ben-David I; Rozen Y; Ortu G; Mishani E
Appl Radiat Isot; 2003 Feb; 58(2):209-17. PubMed ID: 12573320
[TBL] [Abstract][Full Text] [Related]
3. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M
Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817
[TBL] [Abstract][Full Text] [Related]
4. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
Vincent PW; Bridges AJ; Dykes DJ; Fry DW; Leopold WR; Patmore SJ; Roberts BJ; Rose S; Sherwood V; Zhou H; Elliott WL
Cancer Chemother Pharmacol; 2000; 45(3):231-8. PubMed ID: 10663641
[TBL] [Abstract][Full Text] [Related]
5. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2012 Jun; 26(5):381-9. PubMed ID: 22354330
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
8. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer.
Fernandes C; Oliveira C; Gano L; Bourkoula A; Pirmettis I; Santos I
Bioorg Med Chem; 2007 Jun; 15(12):3974-80. PubMed ID: 17449254
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
[TBL] [Abstract][Full Text] [Related]
10. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2011 Feb; 25(2):117-24. PubMed ID: 21058048
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
[TBL] [Abstract][Full Text] [Related]
14. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I
Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
16. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
[TBL] [Abstract][Full Text] [Related]
17. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
[TBL] [Abstract][Full Text] [Related]
18. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
19. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.
Bonasera TA; Ortu G; Rozen Y; Krais R; Freedman NM; Chisin R; Gazit A; Levitzki A; Mishani E
Nucl Med Biol; 2001 May; 28(4):359-74. PubMed ID: 11395308
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
